This opinion corroborates the previous scientific advice from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) GoLiver Therapeutics, a start-up focused on the development of Innovative Therapy Medicines, in particular cell therapy products for life-threatening liver diseases without the need for transplant using differentiated pluripotent stem cells, announces that the European Medicines Agency (EMA) has given a positive scientific advice on its clinical development, pharmaco-toxicological and production strategy plans. With this positive scientific advice, GoLiver Therapeutics has reached an important milestone in its clinical roadmap.
Recent Comments